Electra’s Upsized IPO Lands $350M for New Class of Precision Immunology Drugs
Electra Therapeutics’ IPO cash will support a potential first-in-class drug whose lead indication is a…
Electra’s Upsized IPO Lands $350M for New Class of Precision Immunology Drugs
Electra Therapeutics’ IPO cash will support a potential first-in-class drug whose lead indication is a rare hyperinflammatory disorder with no FDA-approved treatments. Meanwhile, clinical-stage biotechs Marea Therapeutics and Sensorion revealed their respective plans to enter the U.S. public markets. The post Electra’s Upsized IPO Lands $350M for New Class of Precision Immunology Drugs appeared first…
Angle Health Raises $600M to Grow Employer Health Benefits Platform
Angle Health’s funding round was led by Vitruvian Partners, with participation from Town Hall Ventures, Blumberg Capital, Portage Ventures, PruVen Capital and Y Combinator. The post Angle Health Raises $600M to Grow Employer Health Benefits Platform appeared first on MedCity News.
CMS Announces Participants in Landmark Medicaid Drug Payment Model to Bring Down Drug Costs
The initiative involves manufacturers providing drugs at international prices, with rebates and federal savings shared, and runs through 2030 to curb rising drug costs for Medicaid recipients
RFK Jr. Overhauls USPSTF Leadership: 5 Things to Know
HHS Secretary Robert F. Kennedy Jr. named eight new members to the U.S. Preventive Services Task Force this week, completing the 16-seat panel amid ongoing tension over its leadership. The post RFK Jr. Overhauls USPSTF Leadership: 5 Things to Know appeared first on MedCity News.
Two Years After the Change Healthcare Cyberattack, Healthcare Still Has a Clearinghouse Redundancy Problem
What happened was not just a cybersecurity failure, it was an infrastructure failure. The post Two Years After the Change Healthcare Cyberattack, Healthcare Still Has a Clearinghouse Redundancy Problem appeared first on MedCity News.
The Trials Were Always There — Patients Just Couldn’t Find Them
This structural problem calls for a structural solution, requiring no new science, regulation, or data. The post The Trials Were Always There — Patients Just Couldn’t Find Them appeared first on MedCity News.
Health Journalists Visit Conservative Georgia District and Weigh AI Bioweapon Threat
Céline Gounder, KFF Health News’ editor-at-large for public health, discussed the findings of a recent cancer report on CBS News 24/7’s Mornings on Sept. 16. Gounder also discussed the potential of artificial intelligence to be used in developing biological weapons on CBS News’ CBS Mornings on Sept. 11. Click here to watch Gounder on CBS…
Whack-a-Mole AI – The Hugging Face Problem
By MIKE MAGEE On August 29, 2026, METR (Model Evaluation and Threat Research), an independent organization that “evaluates frontier AI models to help companies and wider society understand AI capabilities and what risks they pose,” released a report titled “Brief independent investigation of agents’ behavior, reasoning and collaboration in the OpenAI / Hugging Face hacking…
Ayble Health Secures $16M for Virtual Digestive Health Clinic
Ayble Health’s Series A round was led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx and Accomplice. The post Ayble Health Secures $16M for Virtual Digestive Health Clinic appeared first on MedCity News.
Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo
Ultragenyx Pharmaceutical’s Fayuvi is now the first FDA-approved therapy for the underlying cause of Sanfilippo syndrome type A, an ultra-rare inherited neurological disorder. It’s the second approved gene therapy for Ultragenyx, which specializes in rare disease medicines. The post Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo appeared first on MedCity…
